Kornimate/medical-research-clean huggingface dataset:
octreotide in the prevention of postoperative complications after pancreaticoduodenectomy

Conditions: Periampullary Carcinoma Resectable

Summary: pancreaticoduodenectomy (pd) is the standard operation for treatment of patients with benign and malignant pancreatic and periampullary diseases. despite improved surgical technique and postoperative care, the mortality rate after pd is high reaching up to 30%, due to high incidence of postoperative complications . pancreatic fistula (pf) is the one of the most frequent complications of pd and the major contributor to postoperative morbidity the aim of this study to evaluate the effect of the perioperative octreotide use after pd for prevention of the postoperative pancreatic fistula. the secondary outcomes are overall postoperative complications, mortality and the cost benefit relationship of the use of the perioperative octreotide.

this study will be a prospective randomized controlled trial for perioperative use of octreotide in patients after pd for pancreatic and periampullary tumours from may 2014 to april 2017 in gastroenterology surgical center, mansoura university, egypt. the primary outcome of the study is the effect of perioperative use of octreotide on the rate of development of postoperative pancreatic fistula in patients after pd for pancreatic and periampullary tumours. the secondary outcome is postoperative overall complications, mortality, duration of the hospital length of stay and cost-benefit relationship of perioperative use of octreotide. enrolled patients will be randomized to either the octreotide or the placebo group. the randomization process will be done using closed envelop method and will be withdrawn by a nurse after pancreaticoduodenectomy . patients in the octreotide group will receive sandostatin 100ug sc every 8 hours daily staring from the day of operation to the postoperative day 7. patients in the placebo group will receive saline administered in a similar manner.

Eligibility criteria:
inclusion criteria: 1. all patients with pancreatic and periampullary tumours anticipated for pd will be eligible to participate in this trial. 2. patients with non dilated pancreatic duct and soft pancreas exclusion criteria: exclusion criteria: 1. age over 70. 2. patients who underwent total or distal pancreatic resection. 3. patients with unresectable disease who will undergo any surgical procedure other than pd for pancreatic and periampullary tumours. 4. patients underwent neoadjuvant chemotherapy or radiotherapy. 5. pd more than 3mm. 6. firm pancreas. 7. pj
investigate the relationship between inflammatory and coagulation in sah csf

Conditions: Subarachnoid Hemorrhage, Aneurysmal

Summary: investigate the role of inflammasome and blood coagulation response in human cerebrospinal fluid after subarachnoid hemorrhage.

investigate the role of inflammasome and blood coagulation response in human cerebrospinal fluid after subarachnoid hemorrhage (sah). 1.40 patients with sah will be included. the csf will used for elisa test for inflammatory factors and cogulation factors. 2.csf obtained from 4 patients with non-neuroloogical disease with 4 addittional sah patients will be used for mass spectrometry

Eligibility criteria:
inclusion criteria: * sah patients with modified fisher scale 3-4. exclusion criteria: * patients with history of cns disease (e.g., stroke, traumatic brain injury, cns infection) or accompanied by serious comorbidities before sah onset (e.g., severe coagulation disorders, malignant tumor, uncontrollable heart disease, and hypertension) or other organ dysfunctions within 6 months were excluded from the study

Keywords: subarachnoid hemorrhage coagulation inflammation
efficacy and influencing factors of deep transcranial magnetic stimulation in the treatment of ocd

Conditions: Obsessive-Compulsive Disorder

Summary: this study aims to explore the efficacy and influencing of accelerated dtms (deep transcranial magnetic stimulation) treatment in patients with obsessive-compulsive disorder (ocd), and explores the potential neural mechanisms of treatment effect by magnetic resonance imaging (mri) and electroencephalography (eeg).

the study is to recruit eligible patients with obsessive-compulsive disorder (ocd) from the shanghai mental health center for deep transcranial magnetic stimulation (dtms) intervention, and recruit healthy controls who meet the enrollment criteria from the community. among them, patients with ocd will be randomly divided into a real stimulation group and a sham stimulation group. after baseline assessment, dtms treatment will be administered twice a day. eeg data collection, mri data, cognitive tasks, psychological self-assessment scales and clinical symptom assessment will be conducted before treatment and 2 weeks after treatment. during the treatment process, patients will receive two treatments per day, each lasting 20 minutes, for a total of 2 weeks, or 28 treatments in total.

Eligibility criteria:
inclusion criteria: * aged between 18 and 50, both genders are welcome. * dsm-5 criteria for ocd. * y-bocs total score ≥ 16 despite therapeutic-dose sri treatment or completion of at least one full course of cbt. the treatment regimen must have been stable for at least 8 weeks prior to enrollment and remain unchanged throughout the study. * more than 9 years of education. * right-handed. exclusion criteria: * any additional current psychiatric comorbidity, except for obsessive- compulsive personality disorder. * severe obsessive symptoms prevent the completion of necessary assessments. * has a history of receiving ect therapy. * has received rtms or tdcs treatment within the past two months. * has severe physical illnesses or any physical conditions that can induce epilepsy or intracranial hypertension, including cardiovascular and respiratory diseases, among others. * has a past history of neurological disorders (such as epilepsy, cerebrovascular accidents, etc.) or brain injuries, or a history of brain surgery. * has implanted medical devices such as intracranial stents, cardiac pacemakers, coronary stents, cochlear implants, etc. * serious suicide risk. * pregnancy or nursing of an infant.

Keywords: deep transcranial magnetic stimulation
brown adipose tissue in type 1 diabetes

Conditions: Type1diabetes

Summary: brown adipose tissue has the capacity to consume large amounts of energy and has insulin-independent glucose uptake. the investigators have recently observed an inverse correlation between irisin levels and insulin needs of type 1 diabetes patients. transplantation of brown adipose tissue to insulin-deficient rats normalized their blood glucose levels. in this study 12 patients with long-standing type 1 diabetes (\>10 years) and with variable exogenous insulin needs will be investigated for amount of brown adipose tissue with positron emission tomography using the tracer 18f-deoxy glucose.


Eligibility criteria:
inclusion criteria: 1. adult patients (18 years of age or more) 2. type 1 diabetes diagnose for more than 10 years exclusion criteria: 1. ongoing pregnancy 2. ongoing breast-feeding 3. bmi\<19 4. bmi \>30 5. p-creatinine \<110 µmol/l
a study of jnj-87890387 for advanced solid tumors

Conditions: Advanced Solid Tumors

Summary: the purpose of this study is to determine recommended phase 2 dose(s) (rp2ds) of jnj-87890387 and to determine the safety of jnj-87890387 at the rp2d(s).


Eligibility criteria:
inclusion criteria: * have histologically or cytologically confirmed, metastatic, or unresectable solid tumor of one of the following types: a) renal cell cancer (rcc)-clear cell or papillary carcinoma; b) endometrioid ovarian cancer c) endometrioid uterine carcinoma; d) colorectal adenocarcinoma (crc); e) lung adenocarcinoma * have measurable or evaluable disease: part 1- either measurable or evaluable disease; part 2- at least 1 measurable lesion per recist v1.1. participants with ovarian cancer without a measurable lesion must have disease evaluable per response evaluation criteria in solid tumors (recist v1.1) or have cancer antigen (ca) 125 greater than (\>) 2\*upper limit of normal (uln) during screening * all participants in part 1 and part 2 must consent to provide an archived tumor tissue sample at screening * have an eastern cooperative oncology group (ecog) performance status of 0 to 1 at screening * be willing and able to adhere to the lifestyle restrictions specified in this protocol. exclusion criteria: * active central nervous system (cns) involvement with the exception of locally treated brain metastases that are clinically stable and asymptomatic for \> 2 weeks and who are off or receiving low-dose corticosteroid treatment (less than or equal to \[\<=\]10 milligrams \[mg\] prednisone or equivalent) for at least 2 weeks prior to start of study treatment * toxicity from prior anticancer therapy that has not resolved to grade \<=1 (except alopecia, vitiligo, grade \<=2 peripheral neuropathy, or endocrinopathies that are stable on hormone replacement) * history of grade greater than or equal to (\>=) 2 immune-related ae(s) with prior immunotherapy that led to discontinuation of previous immunotherapy with the exception of grade 2 and grade 3 immune-related aes that responded to treatment and that did not recur following rechallenge. endocrinopathies that are stable on hormone replacement therapy or that have resolved are allowed. * history of solid organ or hematologic stem cell transplantation * any episode of partial or complete bowel obstruction requiring hospitalization within 30 days prior to first dose of study treatment
administration of celecoxib for treatment of intracerebral hemorrhage : a pilot study

Conditions: Intracerebral Hemorrhage

Summary: primary: change of volume of perihematomal edema as assessed by brain ct. secondary: the change of ich volume between the initial and the follow-up ct scans the neurological status at 90 day using e-gos and mrs. the cumulative incidence of major and minor adverse events that occurred during and after hospitalization until the end of the study

1. inclusion/exclusion criteria 1. inclusion criteria * spontaneous intracerebral hemorrhage was documented by ct scanning within 24 hours of the onset of symptoms * supratentorial location of hemorrhage * older than 17 yrs * informed consent before study 2. exclusion criteria * planned surgical evacuation of hematoma within 24hrs * secondary ich such as trauma or aneurysmal rupture * taking anticoagulation previously * pregnancy,known allergy to celecoxib, severe liver or kidney disease, or poor performance state were excluded * other physical condition, making the patient difficult to participate in this study (decided by the neurologist or the physician). 2. other therapy -no limitation of other medications except nsaids, anticoagulation and antiplatelet agent because of aggravating the symptoms 3. study design multicenter, prospective randomized, comparative open with blinded endpoints (probe) trial to assess the safety and effectiveness of administration of celecoxib for 14 days in patients with intracerebral hemorrhage

Eligibility criteria:
inclusion criteria: 1. spontaneous intracerebral hemorrhage was documented by ct scanning within 24 hours of the onset of symptoms 2. supratentorial location of hemorrhage 3. older than 17 yrs exclusion criteria: 1. planned surgical evacuation of hematoma within 24hrs 2. secondary ich due to trauma or aneurismal rupture or etc 3. taking antithrombotics or other nsaids previously 4. pregnancy 5. other physical condition, making the patient difficult to participate the study (decided by the neurologist or the physician).

Keywords: spontaneous intracerebral hemorrhage acute spontaneous, supratentorial intracerebral hemorrhage
valveclip® transcatheter mitral valve repair study

Conditions: Mitral Regurgitation

Summary: the purpose of this clinical trial is to evaluate the effectiveness and safety of the transcatheter mitral valve repair system in the treatment of patients with moderate or above degenerative mitral regurgitation.

this study is a prospective,multi-center, single-arm, safety and performance clinical study.

Eligibility criteria:
inclusion criteria: 1. severe mitral regurgitation≥3+ (moderate or above degenerative mitral regurgitation disease, or with stenosis is included); 2. age≥70 years; or patients who are 60\~70 years old, and the sts risk score indicate that participants are at high risk of traditional surgery or cannot tolerate traditional thoracotomy; 4) left ventricular ejection fraction≥30%； 5) as assessed by multidisciplinary cardiac team (at least two cardiac surgeons/one cardiologist), patients who are at extremely high-risk or unsuitable for routine mitral valve surgery with evaluation; 6) patients who understand the purpose of the trial and volunteer to participate in, sign the informed consent form and are willing to accept relevant examinations and clinical follow-ups. anatomy selection criteria： 1. the regurgitant jet of mitral valve originates from the a2 and p2 (the lesions of a2/p2 in mitral valve causes regurgitation); 2. the width of the mitral valve prolapsed area is ≤15mm, height of prolapse ≤10mm or coaptation depth≤11mm, coaptation height≥2mm, effective length of anterior and posterior leaflets\>1cm (conforming to everest ii recommended mitral valve interventional edge-to-edge repair standards); 3. effective mitral valve orifice area≥ 4.0cm2; 4. no obvious calcification of the mitral valve annulus and valve leaflets; 5. patient's anatomical conditions allow transseptal approach. exclusion criteria: 1. previous cardiac mitral valve surgery; 2. patients with infective endocarditis or having an active infection; 3. patients with mitral regurgitation caused by pure mitral stenosis; 4. combined with untreated severe coronary artery disease 5. pulmonary hypertension (pulmonary artery systolic pressure\>70mmhg); 6. patients with severe right heart failure; 7. patients are extremely weak and cannot tolerate general anesthesia or are in shock that circulatory support is needed; 8. patients with hypertrophic cardiomyopathy, restrictive cardiomyopathy, and constrictive pericarditis; 9. patients receiving chronic dialysis; 10. patients with clear coagulation dysfunction and severe coagulopathy; 11. patients with clear contraindications to anticoagulant drugs; 12. patients with stroke or transient ischemic attack within 30 days; 13. echocardiography found any intracardiac mass, left ventricle or atrial thrombus; 14. patients who require surgery or interventional therapy for other valvular lesions; 15. patients with severe macrovascular lesions requiring surgical treatment; 16. patients' imaging examinations suggest that the anatomy of the heart and valves are inappropriate;
a study of amdx-2011p in participants with caa

Conditions: Cerebral Amyloid Angiopathy

Summary: the purpose of this study is to assess safety, tolerability, plasma pharmacokinetics and biologic activity of a single intravenous dose of amdx-2011p in participants with cerebral amyloid angiopathy (caa).

this open-label, masked endpoint assessment study will evaluate the safety, tolerability, plasma pharmacokinetics (pk) and biological activity of an intravenous (iv) dose of amdx-2011p in participants with caa. assessments of retinal images will be conducted by central masked assessors. participants will be admitted to the study site where eye examination and retinal imaging will be conducted before administration of the study drug. amdx-2011p will be administered through a single iv bolus injection followed by safety assessments, retinal imaging and pk blood collection.

Eligibility criteria:
inclusion criteria: 1. diagnosis of hereditary caa or probable and definite symptomatic or asymptomatic sporadic caa diagnosed through genetic testing or according to the modified boston neuroradiological criteria, who had undergone at least one brain magnetic resonance imaging (mri)prior to entry into study. 2. abnormality consistent with caa on historical mri. 3. in general good health exclusion criteria: 1. presence of any underlying physical or psychological medical condition that, in the opinion of the investigator, would make it unlikely that the participant will complete the study per protocol. 2. clinically significant laboratory abnormalities assessed by the investigator. 3. active malignancy and/or history of malignancy in the past 5 years, with the exception of completely excised non-melanoma skin cancer or low-grade cervical intraepithelial neoplasia. 4. prolonged qtcf (\>450 ms for males and \>470 ms for females),cardiac arrhythmia, or any clinically significant abnormality in the resting ecg, as judged by the investigator.

Keywords: caa
molecular phenotypes for cystic fibrosis lung disease

Conditions: Cystic Fibrosis; Lung Diseases

Summary: the purpose of this study is to develop an integrated view of molecular mechanisms underlying cf lung disease severity.

background: cystic fibrosis (cf) is a recessive genetic disorder caused by mutations in cf transmembrane conductance regulator (cftr) gene. cf has multi-organ involvement, but respiratory disease is the major cause of morbidity and mortality. the median age of survival in cf is only 37 years, but there is a broad range of disease severity in the lung, even among patients with identical cftr genotypes, including deltaf508 homozygotes. design narrative: this project holds great promise for defining a robust molecular phenotype for cf lung disease, which relates to prognosis, and new targets for therapy. by using a large and well-defined population of deltaf508 homozygotes who also have whole genome single nucleotide polymorphism (snp) data, and by studying gene expression across the whole transcriptome in a large number of samples of two relevant tissues (respiratory epithelium and transformed lymphocytes), we will be uniquely positioned to develop an integrated view of molecular mechanisms underlying cf lung disease severity.

Eligibility criteria:
inclusion criteria: * diagnosed with cf * participation in genetic modifiers of cf lung disease study (nct00037765) exclusion criteria: * history of lung transplant * fully anticoagulated or clotting abnormalities * large nosebleed in the last 2 months * acutely ill
comparison of balanced crystalloids and normal saline in septic patients

Conditions: Sepsis; Acute Kidney Injury; Septic Shock; Sepsis, Severe

Summary: in this prospective randomized controlled trial, investigators attempt to study the effects of acetated ringer's solution on the prognosis and renal function of patients with sepsis in intensive care unit compared with normal saline, and provide evidence for current fluid resuscitation strategies for sepsis.

during the study period，either normal saline or acetated ringer's solution will be assigned as resuscitation fluid to the septic patients meeting the inclusion criteria.it is anticipated that about 500 patients will be enrolled during the study period.

Eligibility criteria:
inclusion criteria: * patients diagnosed sepsis aged 18\~75 and accepted therapy in icu exclusion criteria: * need of renal replacement treatment * end-stage renal failure * pregnant woman

Keywords: sepsis intensive care unit acetated ringer's solution aki normal saline prognosis continuous renal replacement therapy
unlimited or restricted fluid intake in patients with heart failure

Conditions: Heart Failure

Summary: heart failure is the most common cause of admission to hospital and is associated with high morbidity and mortality. treatment options consist of medical- and device treatment and self-care strategies, where fluid restriction has been one of the components in the self-care management of patients with chronic heart failure. the medical treatment has progressed and improved over the years and considerably over the last few years, which has decreased symptoms and improved physical function of these patients. despite our great success in the medical treatment of heart failure, we still face challenges in hospital readmissions and treatment strategies. it contributes to the increased need of evidence on, if and how, fluid intake and fluid restriction should be used as a self-care method. fluid restriction as a self-care treatment is still commonly recommended in heart failure management although the scientific clinical evidence is lacking. fluid restriction is associated with a higher degree of thirst and lower rated quality of life, and there is no consensus on how fluid restriction should be used, no plan for individualized treatment and no agreement on how fluid restriction should be a part of the patient self-care treatment. there is therefore a need for knowledge on how heart failure patients are affected by fluid restriction regarding clincal signs and symptoms of heart failure, quality of life, physical function, readmission to hospital or heart failure events. the primary aim of the study is to investigate whether a free fluid intake is safe compared to a restricted fluid intake, regarding clinical signs of heart failure measured as the presence of b-lines and/or an increase in nt-probnp. the secondary aim is to clarify whether an unlimited fluid intake can improve quality of life and reduce thirst without affecting heart failure symptoms, physical activity, hospital readmissions and/or heart failure events.


Eligibility criteria:
inclusion criteria: * diagnosed with left ventricual heart failure (hfref, hfmef) * physical, cognitive and linguistic ability to carry out all aspects of the study exclusion criteria: * reversible cause of hf (thyroid disorders, severe anemia, etc.) * hyponatremia at baseline (sodium \<130 mmol/l) * egfr at baseline \<30ml/min/1.73m2 * scheduled cardiac surgery, coronary intervention (percutaneous coronary intervention or coronary artery bypass graft surgery) within 3 months * myocardial infarction within 3 months * comorbidity for which fluid restriction or unlimited fluid intake is advised * life expectancy \<6 months

Keywords: quality of life intervention thirst distress symptoms physical capacity hospital readmissions lung ultrasound fluid intake b-lines nt-probnp heart failure fluid restriction